Is desmopressin FDA-approved?

Yes. Desmopressin acetate is the active ingredient in multiple FDA-approved drug products, and the approvals are current rather than merely historical: FDA approved DESMODA (desmopressin acetate) oral solution under NDA 219873 on 25 February 2026, on a 505(b)(2) application from Eton Pharmaceuticals received 25 April 2025. The approval letter states the application 'is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.' The labels record an initial U.S. approval in 1978. Other currently marketed applications include DDAVP tablets (NDA 019955), desmopressin acetate injection (NDA 018938) and generic nasal sprays, alongside numerous ANDAs. Approval is always for a specific product and a specific indication, and on this molecule those indications differ by route of administration — the tablets, the injection, the nasal sprays and the oral solution are not approved for the same things.

Can desmopressin nasal spray be used for bedwetting?

Not according to its label. DDAVP Nasal Spray's FDA-approved labeling lists primary nocturnal enuresis under Limitations of Use and gives the reason in section 5.1: 'DDAVP Nasal Spray is not an indicated formulation for the treatment of primary nocturnal enuresis due to a higher risk of hyponatremia and hyponatremic convulsions with the use of the nasal spray formulation compared to desmopressin tablets seen in postmarketing reports.' DDAVP tablets ARE indicated for primary nocturnal enuresis. So the same active ingredient is approved for this use by one route and excluded from it by another, on the basis of harm reported after marketing — which means an inference from the tablets to the spray runs directly against FDA's labeling. The marketed generic desmopressin acetate nasal spray carries the identical limitation. Whether any desmopressin product is appropriate for a particular patient is a decision for a licensed prescriber.

Is desmopressin approved for nocturia?

It was, twice, and both products are now listed as Discontinued on Drugs@FDA. FDA approved NOCTIVA (desmopressin acetate) nasal spray under NDA 201656 on 3 March 2017 and NOCDURNA (desmopressin acetate) sublingual tablets under NDA 022517 on 21 June 2018, each 'indicated for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least 2 times per night to void'. As of 2 August 2026 the Drugs@FDA overview pages for both applications list every product under them with a marketing status of Discontinued. Two things are worth reading precisely. First, the indication was never 'nocturia' — it was nocturia due to nocturnal polyuria, and both labels state that many conditions can cause nocturia and that efficacy and safety were not established for all of them. Second, both labels carried a boxed warning for hyponatremia. Drugs@FDA records a marketing status, not a reason; this record does not claim to know why either product was discontinued.

Does desmopressin have a boxed warning?

It depends on the product, which is the answer people most often get wrong. Desmopressin acetate injection (NDA 018938) carries a boxed warning headed WARNING: HYPONATREMIA, stating the drug 'can cause hyponatremia, which may be life-threatening if severe' and that it is contraindicated in patients at increased risk of severe hyponatremia — including those with excessive fluid intake, illnesses that can cause fluid or electrolyte imbalances, and those using loop diuretics or systemic or inhaled glucocorticoids. The withdrawn nocturia products NOCTIVA and NOCDURNA carried the same boxed warning. The DDAVP tablets label (NDA 019955) does NOT carry a boxed warning: it describes hyponatremia in an ordinary WARNINGS section, noting that desmopressin 'is a potent antidiuretic which, when administered, may lead to water intoxication and/or hyponatremia' and that 'Unless properly diagnosed and treated hyponatremia can be fatal.' The risk is present across the molecule; the regulatory prominence given to it is not uniform, so read the label of the product in hand rather than a label for 'desmopressin'.

Was desmopressin nasal spray recalled?

Yes. On 5 August 2020 FDA posted Ferring Pharmaceuticals US's announcement that it was voluntarily recalling all lots on the market of DDAVP Nasal Spray 10 mcg/0.1 mL, Desmopressin Acetate Nasal Spray 10 mcg/0.1 mL and STIMATE Nasal Spray 1.5 mg/mL to the consumer level, because the products were superpotent — containing 'amounts of desmopressin higher than specified', found during routine testing. The announcement states the risk relates to hyponatremia 'which could eventually lead to seizure, coma, and death', and that a single non-fatal adverse event potentially associated with the issue was reported in the US while the affected product was distributed. FDA's own Enforcement Report classified all three recalls as Class I, its most serious class, initiated 21 July 2020 and terminated 13 October 2023, covering 228,871 nasal sprays across recall numbers D-1504-2020, D-1505-2020 and D-1506-2020. FDA posts company recall announcements as a public service and states it does not endorse either the product or the company.

Is desmopressin on FDA's 503A bulks list?

No — desmopressin appears nowhere in FDA's list of bulk drug substances nominated for use in compounding under section 503A, updated 14 May 2026. It is in none of the three categories, verified by fetching and text-extracting the document on 2 August 2026: zero hits. That absence means something quite different from the absence of BPC-157 or MOTS-c, and reading it the same way would be a mistake. The 503A nomination list exists for bulk drug substances that are neither the subject of a USP monograph nor a component of an FDA-approved drug product. Desmopressin acetate is a component of many approved drug products, so it was never on that track — the same reason bremelanotide is absent. Being absent from the nomination list is therefore neither a permission nor a safety finding here; it is a statement that this substance was never part of that proceeding.

Is desmopressin the same thing as vasopressin?

No. Desmopressin is a synthetic analogue of arginine vasopressin, not vasopressin itself, and FDA's approved labels describe every desmopressin product as 'a vasopressin analog' rather than as vasopressin. The distinction is carried through into what the products are approved for: the desmopressin labels are built around antidiuretic replacement in central diabetes insipidus, primary nocturnal enuresis, hemophilia A and von Willebrand's disease Type I. Note also that all FDA-approved desmopressin products contain the acetate salt, and that their labels state strengths in both desmopressin acetate and desmopressin base terms — NOCTIVA's label, for instance, describes a spray delivering desmopressin acetate 'equivalent to' a stated quantity of desmopressin. A number on a desmopressin product does not necessarily refer to the same thing as the same number on another.

Desmopressin

Also sold as: DDAVP, dDAVP, desmopressin acetate, 1-desamino-8-D-arginine vasopressin, Stimate, Desmoda, Noctiva, Nocdurna, Minirin, Concentraid

Desmopressin is an FDA-approved vasopressin analogue, marketed since an initial U.S. approval in 1978 and still gaining approvals — FDA approved DESMODA (desmopressin acetate) oral solution under NDA 219873 on 25 February 2026 for central diabetes insipidus. Its approved indications differ by ROUTE rather than by molecule: DDAVP tablets (NDA 019955) are indicated for central diabetes insipidus and for primary nocturnal enuresis, while desmopressin acetate injection (NDA 018938) is indicated for central diabetes insipidus, hemophilia A and von Willebrand's disease Type I in patients with factor VIII levels greater than 5%. The DDAVP Nasal Spray label states the spray 'is not an indicated formulation for the treatment of primary nocturnal enuresis due to a higher risk of hyponatremia and hyponatremic convulsions with the use of the nasal spray formulation compared to desmopressin tablets seen in postmarketing reports' — the same molecule, approved for bedwetting by one route and excluded from it by another. The two products FDA approved specifically for nocturia due to nocturnal polyuria, NOCTIVA (NDA 201656, 2017) and NOCDURNA (NDA 022517, 2018), are both listed Discontinued on Drugs@FDA. Desmopressin acetate injection carries a boxed warning for hyponatremia, which the label states can be life-threatening if severe, leading to seizures, coma, respiratory arrest or death; the DDAVP tablets label carries hyponatremia as an ordinary warning with no boxed warning. In 2020 Ferring recalled all marketed lots of three desmopressin nasal sprays to the consumer level for superpotency, and FDA's Enforcement Report classified all three recalls Class I.

Which molecule this is. A synthetic analogue of the endogenous nonapeptide arginine vasopressin (antidiuretic hormone). Every desmopressin product FDA has approved contains the ACETATE salt, and the labels state strengths in both acetate and desmopressin-base terms — NOCTIVA's label, for example, describes its spray as delivering desmopressin acetate 'equivalent to' a smaller quantity of desmopressin. The disambiguation that matters on this record is not the salt and not the sequence: it is the ROUTE. FDA has approved tablets, an oral solution, a sublingual tablet, an injection and several nasal sprays of the same active ingredient, and their approved indications, their limitations of use and even whether they carry a boxed warning differ from one presentation to the next. 'Desmopressin' does not identify a product.

FDA status

FDA-approved

FDA has approved this as a drug. Approval is always for a specific indication and a specific population — check which one, because it is frequently not the use it is marketed for.

FDA-approved, and not only historically — the source here is an FDA approval letter dated 2026-02-25, for a desmopressin acetate product approved this year. The labels record an 'Initial U.S. Approval: 1978'. Cross-checked against Drugs@FDA on 2026-08-02 via the openFDA `drug/drugsfda` endpoint: 38 applications contain desmopressin acetate as an active ingredient, and products under NDA 019955 (DDAVP tablets), NDA 018938 (desmopressin acetate injection), NDA 020355 (STIMATE) and NDA 219873 (DESMODA), plus numerous ANDAs, are present. Approval is always for a specific product, indication and population — read the approval record below, because on this molecule the indications differ by ROUTE.

NDA 219873 approval letter — Desmoda (desmopressin acetate) oral solution — FDA, 25 February 2026

“Please refer to your new drug application (NDA) received April 25, 2025, and your amendments, submitted pursuant to section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Desmoda (desmopressin acetate) oral solution. … We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.”

Checked against the source on 2 August 2026.

Evidence

Proven in humans

Efficacy established by adequate, well-controlled trials in humans.

ADMINISTRATION CHECK RUN, NOT ASSUMED. Four randomised placebo-controlled trials were opened in FDA-approved labeling on 2026-08-02, and in every one desmopressin acetate was ADMINISTERED to human participants who were randomised to it against placebo. It was not measured as an endogenous biomarker — the trap that reduces MOTS-c and TB-500 from an apparent five human RCTs to an actual zero. Named, so the claim is checkable: NOCDURNA Study 1 (237 women randomised, sublingual desmopressin acetate versus placebo, 3 months) and Study 2 (230 men, same design), both in section 14 of the NDA 022517 label; NOCTIVA Trial 1 (612 patients randomised across two active arms and placebo, 12 weeks) and Trial 2 (433 patients, same design), both in section 14 of the NDA 201656 label. READ THE EFFECT SIZES BEFORE READING THE TIER. In NOCDURNA Study 1 the difference from placebo in mean nocturnal voids per night was -0.3 (95% CI -0.5 to -0.1) and in Study 2 -0.4 (95% CI -0.6 to -0.2), from baselines of about three voids per night; the odds ratios for 33% responder status were 2.15 (95% CI 1.36 to 3.41) and 2.02 (95% CI 1.30 to 3.14). NOCTIVA's two trials reported differences from placebo of -0.3 and -0.4 nocturic episodes per night. Statistically separated from placebo, and small. Both products are now listed Discontinued on Drugs@FDA. SCOPE, and it is narrow. This tier attaches to approved desmopressin acetate products used for their approved indications. It does not transfer between routes: FDA's own labeling states that the nasal spray is not an indicated formulation for primary nocturnal enuresis while the tablets are indicated for it, so 'desmopressin works' is not a statement any single trial supports. AN HONEST GAP: the central diabetes insipidus, hemophilia A and von Willebrand's disease Type I indications rest on evidence generated around the 1978 initial U.S. approval. That evidence was NOT opened for this record. Those indications are recorded here from the approved labels, which is a regulatory fact, not a study this record has verified.

NOCDURNA (desmopressin acetate) sublingual tablets — Highlights of Prescribing Information (NDA 022517, original approval) — FDA, 21 June 2018

“The efficacy of NOCDURNA in the treatment of adults with nocturia due to nocturnal polyuria was established in two 3-month randomized, double-blind, placebo-controlled, multicenter trials in adults over 18 years of age. Study 1 enrolled only women and Study 2 enrolled only men.”

Checked against the source on 2 August 2026.

What FDA actually approved

Application: NDA 019955 (DDAVP tablets); NDA 018938 (desmopressin acetate injection); NDA 017922 (DDAVP Nasal Spray); NDA 020355 (STIMATE nasal spray); NDA 219873 (DESMODA oral solution); NDA 201656 (NOCTIVA nasal spray); NDA 022517 (NOCDURNA sublingual tablets); plus numerous ANDAs — DDAVP, Stimate, Desmoda, Noctiva, Nocdurna, Minirin, Concentraid
Approved indication: Central Diabetes Insipidus: DDAVP Tablets are indicated as antidiuretic replacement therapy in the management of central diabetes insipidus and for the management of the temporary polyuria and polydipsia following head trauma or surgery in the pituitary region. DDAVP is ineffective for the treatment of nephrogenic diabetes insipidus. Patients were selected for therapy based on the diagnosis by means of the water deprivation test, the hypertonic saline infusion test, and/or response to antidiuretic hormone. Continued response to DDAVP can be monitored by measuring urine volume and osmolality. Primary Nocturnal Enuresis: DDAVP Tablets are indicated for the management of primary nocturnal enuresis. DDAVP may be used alone or as an adjunct to behavioral conditioning or other non-pharmacologic intervention.
On the discontinuation: `discontinued` is false because desmopressin as a franchise is marketed — DDAVP tablets, desmopressin acetate injection, generic nasal sprays and the 2026-approved DESMODA oral solution all carry a Prescription marketing status on Drugs@FDA. Individual products under this molecule ARE discontinued, and which ones is the interesting part: NOCTIVA (NDA 201656) and NOCDURNA (NDA 022517) — the only two products FDA ever approved for nocturia due to nocturnal polyuria — are both listed Discontinued, as are MINIRIN (NDA 021333), CONCENTRAID (NDA 019776), the DDAVP Nasal Spray products under NDA 017922 and the STIMATE products under NDA 020355. Each is recorded with its own source below.

VERBATIM FROM ONE LABEL ONLY — NDA 019955, DDAVP tablets. This field does NOT describe the other applications, and on this molecule that caveat is the whole point rather than boilerplate. Desmopressin acetate injection (NDA 018938) is indicated for central diabetes insipidus, hemophilia A and von Willebrand's disease Type I, and carries a boxed warning; STIMATE (NDA 020355) is indicated for hemophilia A and von Willebrand's disease Type I and nothing else; DESMODA (NDA 219873) is indicated for central diabetes insipidus only; DDAVP Nasal Spray (NDA 017922) is indicated for central diabetes insipidus and its label expressly states it is NOT indicated for primary nocturnal enuresis — the very use these tablets ARE approved for. Each of those is recorded verbatim against its own label under fdaFindings, so that a claim about seven applications is carried by seven documents. SOURCE NOTE: cited to DailyMed because Drugs@FDA holds no label document for NDA 019955 newer than a combined 2007 PDF. The wording above was confirmed identical in that 2007 accessdata PDF and in the openFDA `drug/label` record for the same SPL set id, both read on 2026-08-02.

DDAVP (desmopressin acetate) tablets — full prescribing information (SPL, NDA 019955) — DailyMed (U.S. National Library of Medicine), 3 February 2021Checked against the source on 2 August 2026.

What FDA found

FDA’s own words. These are the most citable thing on this site, and the least likely to appear anywhere funded by someone selling the compound.

Desmopressin acetate injection (NDA 018938) is indicated for central (cranial) diabetes insipidus and for the management of the temporary polyuria and polydipsia following head trauma or surgery in the pituitary region; for hemophilia A in patients with factor VIII coagulant activity levels greater than 5%, to maintain hemostasis during surgical procedures and postoperatively or reduce bleeding with episodes of spontaneous or traumatic injuries; and for von Willebrand's disease (Type I) in patients with mild to moderate disease with factor VIII levels greater than 5%. The label states it is ineffective and not indicated for nephrogenic diabetes insipidus, and not indicated for severe Type I von Willebrand's disease or where there is evidence of an abnormal molecular form of factor VIII antigen.
The haematology half of this molecule's identity, and the gating is easy to miss. Both bleeding-disorder indications are restricted to patients with factor VIII levels above 5%, and the label carves out severe Type I von Willebrand's disease explicitly. This is not a general haemostatic agent. PROVENANCE, because the record would otherwise look inconsistent: Drugs@FDA lists the brand name on this NDA as DDAVP with sponsor 'J MOLNER', while the current SPL is published as 'Desmopressin Acetate injection' by Nordic Pharma. The indications text above was confirmed in both the 2022 accessdata label PDF cited here and the current SPL (effective 2025-10-23) read via openFDA `drug/label` on 2026-08-02.
DDAVP (desmopressin acetate) injection — Highlights of Prescribing Information (NDA 018938, supplement 39) — FDA, 21 July 2022
“DDAVP Injection is a vasopressin analog used for: • Central Diabetes Insipidus … • Hemophilia A - for patients with factor VIII coagulant activity levels greater than 5% to maintain hemostasis during surgical procedures and postoperatively or reduce bleeding with episodes of spontaneous or traumatic injuries such as hemarthroses, intramuscular hematomas, or mucosal bleeding. • von Willebrand's disease (Type I) - for patients with mild to moderate disease with factor VIII levels greater than 5% …”
Checked against the source on 2 August 2026.
The FDA-approved labeling for DDAVP Nasal Spray (NDA 017922) states that the product is NOT indicated for the treatment of primary nocturnal enuresis, and gives the reason: a higher risk of hyponatremia and hyponatremic convulsions with the nasal spray formulation compared with desmopressin tablets, seen in postmarketing reports.
The single most useful finding on this record, and the site's thesis stated by FDA about an approved drug rather than about a research chemical. Same active ingredient, same indication sought, two routes — and FDA's labeling approves one and expressly excludes the other, on postmarketing harm. Anyone reasoning 'the tablets are approved for bedwetting, so the spray must be fine for it' is contradicted by the spray's own label. SCOPE: verified in the NDA 017922 reference label cited here. The currently marketed generic desmopressin acetate nasal spray SPL (ANDA 074830, Bausch, effective 2025-06-19) was read on 2026-08-02 and carries the identical Limitation of Use, so this is not an artifact of a discontinued brand label.
DDAVP (desmopressin acetate) nasal spray — Highlights of Prescribing Information (NDA 017922, supplement 46) — FDA, 22 October 2018
“DDAVP Nasal Spray is not an indicated formulation for the treatment of primary nocturnal enuresis due to a higher risk of hyponatremia and hyponatremic convulsions with the use of the nasal spray formulation compared to desmopressin tablets seen in postmarketing reports.”
Checked against the source on 2 August 2026.
STIMATE nasal spray (NDA 020355) is indicated only for hemophilia A and for von Willebrand's disease (Type I), each restricted to patients with factor VIII levels greater than 5%. It carries no diabetes insipidus indication and no nocturia or enuresis indication.
Two nasal sprays of the same active ingredient, sold under the same sponsor, with non-overlapping indications: DDAVP Nasal Spray is approved for central diabetes insipidus and STIMATE is not; STIMATE is approved for hemophilia A and von Willebrand's disease and DDAVP Nasal Spray is not. They differ in concentration, and the label identifies STIMATE as a 150 mcg per 0.1 mL spray in a 2.5 mL bottle. 'Desmopressin nasal spray' names neither product.
STIMATE (desmopressin acetate) nasal spray — Highlights of Prescribing Information (NDA 020355, supplement 22) — FDA, 15 July 2026
“STIMATE is a vasopressin analog used for: • Hemophilia A - for patients with factor VIII coagulant activity levels greater than 5% … • von Willebrand's disease (Type I) - for patients with mild to moderate disease with factor VIII levels greater than 5% … Limitations of Use STIMATE is not indicated for: • von Willebrand's disease (severe Type I) …”
Checked against the source on 2 August 2026.
A MARKETING-STATUS CONTRADICTION IN FDA'S OWN RECORDS, unresolved. Drugs@FDA lists both STIMATE products under NDA 020355 as Discontinued. In the same period FDA approved supplement 22 to that NDA on 2026-07-15, a new STIMATE prescribing information was published with an effective date of 2026-07-22, and the FDA National Drug Code Directory carries an active Stimate listing (NDC 55566-3000, Ferring Pharmaceuticals Inc., marketing start 2025-06-25, listing expiration 2027-12-31) with no marketing end date.
Recorded as a contradiction rather than resolved, because resolving it would mean guessing. The most likely reading is that the Drugs@FDA product rows still describe the older CSL Behring presentation (NDC 0053-6871, the one recalled in 2020) while Ferring has relisted the product under a new NDC — but that is an inference, not a document. What is documented: the discontinuation flag and the active NDC listing are both current FDA records and they disagree. Verified 2026-08-02 against the Drugs@FDA overview page cited here, the openFDA `drug/drugsfda` record for NDA 020355, the openFDA `drug/ndc` record for NDC 55566-3000, and the supplement 22 label PDF. Anyone relying on STIMATE availability should check with the sponsor rather than with this record.
Drugs@FDA — NDA 020355 (STIMATE), products and marketing status — FDA, 15 July 2026Checked against the source on 2 August 2026.
NOCTIVA (desmopressin acetate) nasal spray was approved on 2017-03-03 under NDA 201656 as a vasopressin analog indicated for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least 2 times per night to void, with a Limitation of Use that it was not studied in patients younger than 50 years of age. Drugs@FDA lists both NOCTIVA products as Discontinued.
Read the indication precisely, because 'approved for nocturia' is not what it says. The approval is for nocturia DUE TO NOCTURNAL POLYURIA — one cause among many — and the label says so in terms: 'Many conditions can cause nocturia. The efficacy and safety of NOCTIVA have not been established for all causes of nocturia.' The label also carried a boxed warning for hyponatremia. The Discontinued status is from the Drugs@FDA overview page for NDA 201656, fetched 2026-08-02; it is a marketing fact and this record does not claim to know the sponsor's reason for it.
NOCTIVA (desmopressin acetate) nasal spray — Highlights of Prescribing Information (NDA 201656, original approval) — FDA, 3 March 2017
“NOCTIVA is a vasopressin analog indicated for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least 2 times per night to void. (1) Limitation of Use: Not studied in patients younger than 50 years of age. (1)”
Checked against the source on 2 August 2026.
NOCDURNA (desmopressin acetate) sublingual tablets were approved on 2018-06-21 under NDA 022517 as a vasopressin analog indicated for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least 2 times per night to void. Drugs@FDA lists both NOCDURNA products as Discontinued.
The second and last of FDA's nocturia-specific desmopressin approvals, and it is also listed Discontinued. NOCDURNA's label likewise states that 'Many conditions can cause nocturia' and that its efficacy and safety 'have not been established for the treatment of all causes of nocturia'. It carried a boxed warning for hyponatremia and an unusually long contraindication list including heart failure, uncontrolled hypertension, polydipsia, SIADH and an estimated glomerular filtration rate below 50 mL/min/1.73 m2. Discontinued status verified on the Drugs@FDA overview page for NDA 022517, 2026-08-02.
NOCDURNA (desmopressin acetate) sublingual tablets — Highlights of Prescribing Information (NDA 022517, original approval) — FDA, 21 June 2018
“NOCDURNA is a vasopressin analog indicated for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least 2 times per night to void. (1)”
Checked against the source on 2 August 2026.
FDA approved DESMODA (desmopressin acetate) oral solution on 2026-02-25 under NDA 219873, submitted pursuant to section 505(b)(2), indicated for the management of central diabetes insipidus as antidiuretic replacement therapy for adults and pediatric patients, and not indicated for nephrogenic diabetes insipidus.
The newest desmopressin approval, and worth recording because it shows the direction of travel. A molecule approved in 1978 gained a NEW presentation in 2026 — and that presentation was approved for the narrowest of the historical indications, central diabetes insipidus alone. It carries no enuresis, nocturia, hemophilia or von Willebrand's indication. Approval pathway confirmed in the FDA approval letter: a 505(b)(2) application received 2025-04-25 from Eton Pharmaceuticals.
DESMODA (desmopressin acetate) oral solution — Highlights of Prescribing Information (NDA 219873) — FDA, 25 February 2026
“DESMODA is a vasopressin analog indicated for the management of central diabetes insipidus as antidiuretic replacement therapy for adults and pediatric patients. Limitations of Use • DESMODA is not indicated for the treatment of nephrogenic diabetes insipidus.”
Checked against the source on 2 August 2026.
Desmopressin appears nowhere in FDA's list of bulk drug substances nominated for use in compounding under section 503A, updated 2026-05-14 — not in Category 1, Category 2 or Category 3.
Recorded to close a misreading, not to assert a status, and the difference matters. Verified by fetching and text-extracting the document directly on 2026-08-02: zero hits for 'desmopressin' anywhere in it. This absence means something entirely different from BPC-157's absence. The 503A nomination list is a route for substances that are NOT components of approved drug products; desmopressin acetate is a component of dozens. Its absence is the same kind of absence as bremelanotide's — it was never on that track — and it is neither a permission nor a safety finding. This record therefore carries no compoundingStatus at all, because asserting 'never-nominated' would imply a proceeding desmopressin was never part of.
Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act — FDA, 14 May 2026Checked against the source on 2 August 2026.

Documented safety signals

Boxed warning — HYPONATREMIA, on desmopressin acetate injection (NDA 018938). The label states the drug can cause hyponatremia, which may be life-threatening if severe, and that it is contraindicated in patients at increased risk of severe hyponatremia, such as patients with excessive fluid intake, illnesses that can cause fluid or electrolyte imbalances, and in those using loop diuretics or systemic or inhaled glucocorticoids.
FDA's highest-level warning, and the reason this record insists on naming products rather than the molecule. The boxed warning is NOT uniform across desmopressin: it appears on the injection, on NOCTIVA and on NOCDURNA, and the DDAVP tablets label (NDA 019955) carries hyponatremia in an ordinary WARNINGS section with no boxed warning at all. Both labels were read on 2026-08-02. The boxed warning also requires serum sodium monitoring before and during treatment — a screening step nobody obtaining an unprescribed product is asked to take, because there is no prescriber to ask it. The elisions above remove specific monitoring intervals under this site's no-dosing policy; no finding depends on them.
DDAVP (desmopressin acetate) injection — Highlights of Prescribing Information (NDA 018938, supplement 39) — FDA, 21 July 2022
“WARNING: HYPONATREMIA … DDAVP can cause hyponatremia, which may be life-threatening if severe. (5.1) • DDAVP is contraindicated in patients at increased risk of severe hyponatremia, such as patients with excessive fluid intake, illnesses that can cause fluid or electrolyte imbalances, and in those using loop diuretics or systemic or inhaled glucocorticoids. (4, 5.1) … • If hyponatremia occurs, interrupt or discontinue DDAVP. (5.1)”
Checked against the source on 2 August 2026.
The full prescribing information for desmopressin acetate states that severe hyponatremia can be life-threatening, leading to seizures, coma, respiratory arrest, or death.
Stated plainly because desmopressin is frequently described as a benign, long-established drug, and the mechanism of harm is not intuitive. The risk is not toxicity of the peptide — it is water retention. The labels attribute hyponatremia to excessive fluid intake while urine output is limited by the antidiuretic effect, which is why every label carries a fluid-restriction instruction and why the pediatric and geriatric warnings are the strongest. The quote above is from the current SPL wording read via openFDA `drug/label` on 2026-08-02; the 2022 label PDF cited here carries the same finding in the boxed warning and section 5.1.
DDAVP (desmopressin acetate) injection — Highlights of Prescribing Information (NDA 018938, supplement 39) — FDA, 21 July 2022
“Desmopressin acetate injection can cause hyponatremia. Severe hyponatremia can be life-threatening if it is not promptly diagnosed and treated, leading to seizures, coma, respiratory arrest, or death”
Checked against the source on 2 August 2026.
CLASS I RECALL, 2020. Ferring Pharmaceuticals US voluntarily recalled all lots on the market of DDAVP Nasal Spray 10 mcg/0.1 mL, Desmopressin Acetate Nasal Spray 10 mcg/0.1 mL and STIMATE Nasal Spray 1.5 mg/mL to the consumer level, due to superpotency — amounts of desmopressin higher than specified, found during routine testing. FDA's Enforcement Report classifies all three recalls as Class I.
A manufacturing failure at an approved, decades-old product, which is the honest counterweight to this record's own framing. Approval buys you a specification and a recall mechanism; it does not buy you a guarantee that every vial met the spec. What it does buy is that the deviation was found in routine testing, published, classified and acted on — none of which exists for an unapproved product. Note the company's own statement of the harm: 'To date, Ferring has not received an increase in adverse event reports due to increased concentrations of desmopressin from users of the nasal spray. A single non-fatal adverse event potentially associated with this issue was reported in the US during the timeframe that the affected product was distributed.' This is a company announcement that FDA posts as a public service; FDA states it does not endorse either the product or the company.
Ferring US Issues Voluntary Nationwide Recall of DDAVP Nasal Spray, Desmopressin Acetate Nasal Spray and STIMATE Nasal Spray Due to Superpotency — FDA, 5 August 2020
“These products are being recalled due to superpotency or amounts of desmopressin higher than specified. These out of specification results were obtained during routine testing. The risks associated with higher than specified amounts of desmopressin relate to abnormally low levels of sodium in the blood (i.e., hyponatremia) which could eventually lead to seizure, coma, and death.”
Checked against the source on 2 August 2026.
FDA's Enforcement Report records three Class I recalls initiated 2020-07-21 for 'Superpotent Drug', covering 29,371 STIMATE nasal sprays (D-1506-2020), 184,325 desmopressin acetate nasal sprays (D-1505-2020) and 15,175 DDAVP nasal sprays (D-1504-2020), all distributed nationwide within the United States. All three were terminated 2023-10-13.
Recorded separately from the company announcement because it carries what the announcement does not: FDA's own classification and the quantities. Class I is FDA's most serious recall class. The three recall numbers together cover 228,871 units. Verified via the openFDA `drug/enforcement` endpoint on 2026-08-02; the URL cited is the exact query returning record D-1506-2020.
FDA Enforcement Report — recall D-1506-2020 (STIMATE nasal spray), with companion recalls D-1504-2020 and D-1505-2020 — FDA, 26 August 2020
“Superpotent Drug”
Checked against the source on 2 August 2026.
Labeled warnings and precautions for desmopressin acetate injection, beyond hyponatremia, include hypotension with compensatory increase in heart rate or hypertension; increased risk of thrombosis in patients with von Willebrand's disease Type IIB, due to platelet aggregation; severe hypersensitivity reactions; and fluid retention, with the label stating it is not recommended in patients at risk for increased intracranial pressure or with a history of urinary retention.
The Type IIB von Willebrand's signal deserves separate attention because it inverts the indication: desmopressin is approved for Type I von Willebrand's disease and the label makes Type IIB a contraindication on the injection, on the basis of thrombosis from platelet aggregation. A patient who knows only that 'desmopressin treats von Willebrand's' has the subtype backwards half the time. Verified in both the 2022 label PDF cited here and the current SPL read via openFDA `drug/label` on 2026-08-02.
DDAVP (desmopressin acetate) injection — Highlights of Prescribing Information (NDA 018938, supplement 39) — FDA, 21 July 2022
“Increased Risk of Thrombosis in Patients with von Willebrand's Disease Type IIB : Use of desmopressin acetate in patients with Type IIB von Willebrand's disease may cause thrombosis due to platelet aggregation. (5.3)”
Checked against the source on 2 August 2026.
The FDA-approved labeling for DDAVP Nasal Spray states that chronic administration may result in changes to nasal mucosa, and that nasal mucosa abnormalities such as scarring and edema — whether from chronic administration or other causes including nasal blockage, mucosal atrophy, severe atrophic rhinitis or recent nasal surgery — may cause erratic, unreliable absorption.
A route-specific failure mode with no equivalent for the tablets, and one that compounds the superpotency problem: a product whose absorption is described by its own label as potentially 'erratic, unreliable' is a product where the amount actually delivered is uncertain in both directions. The label's own remedy is to avoid the nasal route in such patients and consider other formulations of desmopressin acetate given by other routes.
DDAVP (desmopressin acetate) nasal spray — Highlights of Prescribing Information (NDA 017922, supplement 46) — FDA, 22 October 2018
“Chronic administration of DDAVP Nasal Spray may result in changes to nasal mucosa. Nasal mucosa abnormalities (such as scarring and edema) due to chronic administration, or due to other causes … may cause erratic, unreliable absorption.”
Checked against the source on 2 August 2026.

Questions people actually ask

Every answer cites the document behind it. Where the honest answer is “nobody knows”, that is the answer you will get.

Is desmopressin FDA-approved?: Yes. Desmopressin acetate is the active ingredient in multiple FDA-approved drug products, and the approvals are current rather than merely historical: FDA approved DESMODA (desmopressin acetate) oral solution under NDA 219873 on 25 February 2026, on a 505(b)(2) application from Eton Pharmaceuticals received 25 April 2025. The approval letter states the application 'is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.' The labels record an initial U.S. approval in 1978. Other currently marketed applications include DDAVP tablets (NDA 019955), desmopressin acetate injection (NDA 018938) and generic nasal sprays, alongside numerous ANDAs. Approval is always for a specific product and a specific indication, and on this molecule those indications differ by route of administration — the tablets, the injection, the nasal sprays and the oral solution are not approved for the same things.
NDA 219873 approval letter — Desmoda (desmopressin acetate) oral solution — FDA, 25 February 2026
“This NDA provides for the use of Desmoda (desmopressin acetate) oral solution for the management of central diabetes insipidus as antidiuretic replacement therapy for adults and pediatric patients. … It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.”
Checked against the source on 2 August 2026.
Can desmopressin nasal spray be used for bedwetting?: Not according to its label. DDAVP Nasal Spray's FDA-approved labeling lists primary nocturnal enuresis under Limitations of Use and gives the reason in section 5.1: 'DDAVP Nasal Spray is not an indicated formulation for the treatment of primary nocturnal enuresis due to a higher risk of hyponatremia and hyponatremic convulsions with the use of the nasal spray formulation compared to desmopressin tablets seen in postmarketing reports.' DDAVP tablets ARE indicated for primary nocturnal enuresis. So the same active ingredient is approved for this use by one route and excluded from it by another, on the basis of harm reported after marketing — which means an inference from the tablets to the spray runs directly against FDA's labeling. The marketed generic desmopressin acetate nasal spray carries the identical limitation. Whether any desmopressin product is appropriate for a particular patient is a decision for a licensed prescriber.
DDAVP (desmopressin acetate) nasal spray — Highlights of Prescribing Information (NDA 017922, supplement 46) — FDA, 22 October 2018
“DDAVP Nasal Spray is not indicated for: • Treatment of nephrogenic diabetes insipidus, • Treatment of primary nocturnal enuresis [see Warnings and Precautions (5.1)] …”
Checked against the source on 2 August 2026.
Is desmopressin approved for nocturia?: It was, twice, and both products are now listed as Discontinued on Drugs@FDA. FDA approved NOCTIVA (desmopressin acetate) nasal spray under NDA 201656 on 3 March 2017 and NOCDURNA (desmopressin acetate) sublingual tablets under NDA 022517 on 21 June 2018, each 'indicated for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least 2 times per night to void'. As of 2 August 2026 the Drugs@FDA overview pages for both applications list every product under them with a marketing status of Discontinued. Two things are worth reading precisely. First, the indication was never 'nocturia' — it was nocturia due to nocturnal polyuria, and both labels state that many conditions can cause nocturia and that efficacy and safety were not established for all of them. Second, both labels carried a boxed warning for hyponatremia. Drugs@FDA records a marketing status, not a reason; this record does not claim to know why either product was discontinued.
Drugs@FDA — NDA 022517 (NOCDURNA), products and marketing status — FDA, 21 June 2018Checked against the source on 2 August 2026.
Does desmopressin have a boxed warning?: It depends on the product, which is the answer people most often get wrong. Desmopressin acetate injection (NDA 018938) carries a boxed warning headed WARNING: HYPONATREMIA, stating the drug 'can cause hyponatremia, which may be life-threatening if severe' and that it is contraindicated in patients at increased risk of severe hyponatremia — including those with excessive fluid intake, illnesses that can cause fluid or electrolyte imbalances, and those using loop diuretics or systemic or inhaled glucocorticoids. The withdrawn nocturia products NOCTIVA and NOCDURNA carried the same boxed warning. The DDAVP tablets label (NDA 019955) does NOT carry a boxed warning: it describes hyponatremia in an ordinary WARNINGS section, noting that desmopressin 'is a potent antidiuretic which, when administered, may lead to water intoxication and/or hyponatremia' and that 'Unless properly diagnosed and treated hyponatremia can be fatal.' The risk is present across the molecule; the regulatory prominence given to it is not uniform, so read the label of the product in hand rather than a label for 'desmopressin'.
DDAVP (desmopressin acetate) injection — Highlights of Prescribing Information (NDA 018938, supplement 39) — FDA, 21 July 2022
“WARNING: HYPONATREMIA See full prescribing information for complete boxed warning. • DDAVP can cause hyponatremia, which may be life-threatening if severe. (5.1)”
Checked against the source on 2 August 2026.
Was desmopressin nasal spray recalled?: Yes. On 5 August 2020 FDA posted Ferring Pharmaceuticals US's announcement that it was voluntarily recalling all lots on the market of DDAVP Nasal Spray 10 mcg/0.1 mL, Desmopressin Acetate Nasal Spray 10 mcg/0.1 mL and STIMATE Nasal Spray 1.5 mg/mL to the consumer level, because the products were superpotent — containing 'amounts of desmopressin higher than specified', found during routine testing. The announcement states the risk relates to hyponatremia 'which could eventually lead to seizure, coma, and death', and that a single non-fatal adverse event potentially associated with the issue was reported in the US while the affected product was distributed. FDA's own Enforcement Report classified all three recalls as Class I, its most serious class, initiated 21 July 2020 and terminated 13 October 2023, covering 228,871 nasal sprays across recall numbers D-1504-2020, D-1505-2020 and D-1506-2020. FDA posts company recall announcements as a public service and states it does not endorse either the product or the company.
Ferring US Issues Voluntary Nationwide Recall of DDAVP Nasal Spray, Desmopressin Acetate Nasal Spray and STIMATE Nasal Spray Due to Superpotency — FDA, 5 August 2020
“Ferring Pharmaceuticals US is voluntarily recalling all lots on the market of DDAVP® Nasal Spray 10 mcg/0.1mL, Desmopressin Acetate Nasal Spray 10 mcg/0.1mL, and STIMATE® Nasal Spray 1.5 mg/mL listed in the table below to the consumer level. These products are being recalled due to superpotency or amounts of desmopressin higher than specified.”
Checked against the source on 2 August 2026.
Is desmopressin on FDA's 503A bulks list?: No — desmopressin appears nowhere in FDA's list of bulk drug substances nominated for use in compounding under section 503A, updated 14 May 2026. It is in none of the three categories, verified by fetching and text-extracting the document on 2 August 2026: zero hits. That absence means something quite different from the absence of BPC-157 or MOTS-c, and reading it the same way would be a mistake. The 503A nomination list exists for bulk drug substances that are neither the subject of a USP monograph nor a component of an FDA-approved drug product. Desmopressin acetate is a component of many approved drug products, so it was never on that track — the same reason bremelanotide is absent. Being absent from the nomination list is therefore neither a permission nor a safety finding here; it is a statement that this substance was never part of that proceeding.
Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act — FDA, 14 May 2026Checked against the source on 2 August 2026.
Is desmopressin the same thing as vasopressin?: No. Desmopressin is a synthetic analogue of arginine vasopressin, not vasopressin itself, and FDA's approved labels describe every desmopressin product as 'a vasopressin analog' rather than as vasopressin. The distinction is carried through into what the products are approved for: the desmopressin labels are built around antidiuretic replacement in central diabetes insipidus, primary nocturnal enuresis, hemophilia A and von Willebrand's disease Type I. Note also that all FDA-approved desmopressin products contain the acetate salt, and that their labels state strengths in both desmopressin acetate and desmopressin base terms — NOCTIVA's label, for instance, describes a spray delivering desmopressin acetate 'equivalent to' a stated quantity of desmopressin. A number on a desmopressin product does not necessarily refer to the same thing as the same number on another.
DESMODA (desmopressin acetate) oral solution — Highlights of Prescribing Information (NDA 219873) — FDA, 25 February 2026
“DESMODA is a vasopressin analog indicated for the management of central diabetes insipidus as antidiuretic replacement therapy for adults and pediatric patients.”
Checked against the source on 2 August 2026.